ClinicalTrials.gg
WithdrawnNCT05118763Updated Apr 14, 2022

Intranasal INNA-051 for Prevention of COVID-19 in Adults

A Phase 2 interventional study of INNA-051 and Placebo in COVID-19 Pandemic, sponsored by ENA Respiratory Pty Ltd. Withdrawn. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-14.

Sponsored by ENA Respiratory Pty Ltd · Phase 2, Interventional, and Prevention

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Read the detailed description

Adults who have a household member with RT-PCR-confirmed SARS-CoV-2 infection and have been in close contact, and who test negative to SARS-CoV-2, will be randomized. Participants will receive 4 doses of study medication over a 10 day period, and complete symptoms scores and questionnaires. Development of COVID-19 symptoms will require collection of a nasal swab for RT-PCR testing.

Telephone visits will occur on Days 2, 4, 10, 21, 28, and 35. Additional visits will occur on Days 7, 14, and 42 (end of study).

02

Conditions studied

  • COVID-19 Pandemic

Browse trials for

03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

ENA Respiratory Pty Ltd is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of understanding the written , provides signed written informed consent, and agrees to comply with protocol requirements.
  2. Male or female aged ≥18 years.
  3. Must have a symptomatic household contact ("index case") with rapid antigen/point of-care or RT-PCR-confirmed SARS-CoV-2 infection and onset of symptoms in the household contact within 5 days prior to screening.
  4. Participants of non-. Non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or vasectomy) or (amenorrhea for at least 12 months prior to screening without an alternative medical cause).

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to INNA-051.
  2. Previous receipt of any full primary series SARS-CoV-2 vaccine or receipt of a booster vaccination following a full primary series within 12 months of screening.
  3. Any symptoms of COVID-19 within 72 hours prior to screening. Symptoms may include fever (≥38°C), cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and/or smell, shortness of breath, or difficulty breathing.
  4. History of RT-PCR-confirmed SARS-CoV-2 infection within 6 months prior to screening.
  5. Positive point-of-care rapid SARS-CoV-2 diagnostic test at the time of screening.
  6. ≥35 kg/m2.
  7. History of , current chronic virus or virus infection or current tuberculosis.
  8. History of chronic kidney disease (Stage 3 or higher).
  9. Chronic lung disease (, moderate-to-severe poorly controlled asthma [as evident within the last month of awakening with asthma symptoms 1 or more times/week or use of short-acting beta-agonists 3 or more times/week], interstitial lung disease, cystic fibrosis, pulmonary hypertension).
  10. History of significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis.
  11. Current uncontrolled hypertension defined as average of 3 systolic blood pressure readings of ≥140 mmHg or an average of 3 diastolic blood pressure ≥90 mmHg.
  12. History of chronic liver disease or documented evidence of liver fibrosis or cirrhosis.
  13. History of hemoglobinopathy (sickle cell disease, thalassemia).
  14. Chronic use of inhaled substances including tobacco, nicotine vapor, or cannabis (average of ≥5 cigarettes a day for ≥1 month within 1 year of screening or a 10 pack year history or equivalent).
  15. History of neurological or neurodevelopmental conditions (e.g., Down's syndrome, dementia, migraine, epilepsy, stroke, seizure in the last 3 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis, or transverse myelitis).
  16. History of in the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  17. History of immunodeficiency or chronic use (more than 14 continuous days) of any medication that may be associated with changes in the immune function including, but not limited to, systemic exceeding 10 mg/day of prednisone equivalent, allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or toxic drugs within 6 months of screening. Note: The use of low-dose topical and ophthalmic steroid preparations is permitted.
  18. Use of nasal sprays (including but not limited to nasal glucocorticoids), intranasal washes, or other intranasal applications within 7 days prior to screening, or planned use during the study period.
  19. Known allergy or sensitivity or to study drug or its .
  20. Treatment with any other therapy or device within 30 days or within 5 half-lives, whichever is longer, prior to screening.
  21. Female participants who are pregnant or trying to become pregnant, or who are breastfeeding.
  22. Known history of substance abuse that in the investigator's judgment would prevent participant from providing or being able to comply with study procedures.
  23. Other severe, acute, or chronic medical or psychiatric condition(s) that may increase the risk associated with study participation or interfere with the participant's ability to comply with study procedures
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    INNA-051 arm 1

    INNA-051 intranasal spray low dose administered once on each of Days 1, 4, 7 and 10

    Drug: INNA-051

  • Experimental
    INNA-051 arm 2

    INNA-051 intranasal spray high dose administered once on each of Days 1, 4, 7 and 10

    Drug: INNA-051

  • Placebo comparator
    Placebo

    Placebo intranasal spray high dose administered once on each of Days 1, 4, 7 and 10

    Other: Placebo

Interventions

  • Liquid for intranasal administration

  • OtherPlacebo

    Liquid for intranasal administration

06

What researchers measure

Primary outcomes

  1. Evaluate the ability of INNA-051 to reduce the incidence of symptomatic RT-PCR confirmed SARS-CoV-2 infection

    Incidence of symptomatic RT PCR confirmed SARS CoV 2 infection

    Time frame: To Day 14

  2. Evaluate the safety and tolerability of INNA 051.

    Treatment emergent adverse events

    Time frame: To Day 42

Secondary outcomes

  1. Evaluate the ability of INNA 051 to reduce the severity of symptoms in adults who develop RT PCR confirmed SARS CoV-2 infection after randomization

    Incidences of RT PCR confirmed moderate or severe SARS-CoV-2 infection, or COVID 19 related death

    Time frame: To Day 14 and to Day 28

  2. Evaluate the ability of INNA 051 to reduce the severity of symptoms in adults who develop RT PCR confirmed SARS CoV-2 infection after randomization

    Incidences of RT-PCR confirmed severe SARS-CoV-2 infection, or COVID-19-related death

    Time frame: To Day 14 and to Day 28

  3. Evaluate the ability of INNA 051 to reduce the severity of symptoms in adults who develop RT PCR confirmed SARS CoV-2 infection after randomization

    Modified FLU-PRO© total scores

    Time frame: On Day 14 and Day 28

  4. Evaluate the ability of INNA 051 to reduce the severity of symptoms in adults who develop RT PCR confirmed SARS CoV-2 infection after randomization

    Modified FLU-PRO subscale scores for symptom severity by body system (nose, throat, eyes, chest/respiratory and gastrointestinal) in participants with RT PCR confirmed SARS CoV-2 infection

    Time frame: On Day 14 and Day 28

  5. Evaluate the ability of INNA 051 to reduce the incidence of RT PCR confirmed SARS CoV-2 infection

    Incidence of symptomatic RT-PCR-confirmed SARS CoV-2 infection confirmed SARS CoV-2 infection

    Time frame: To Day 28

  6. Evaluate the ability of INNA 051 to reduce the incidence of RT PCR confirmed SARS CoV-2 infection

    Incidence of RT PCR confirmed SARS CoV-2 infection, through Day 14 and Day 28

    Time frame: To Day 14 and to Day 28

  7. Evaluate the ability of INNA 051 to reduce COVID 19 related healthcare utilization

    Incidences of COVID 19 related emergency room visits, hospitalizations, or COVID 19 related death among participants with RT PCR confirmed SARS CoV-2 infection

    Time frame: To Day 14 and to Day 28

  8. Evaluate the ability of INNA 051 to reduce COVID 19 related healthcare utilization

    2. Incidences of COVID 19 related medically attended visits (telemedicine, physician office, urgent care center, emergency room, hospitalization) or COVID 19 related death among participants with RT PCR-confirmed SARS CoV-2 infection

    Time frame: To Day 14 and to Day 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — No plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2022; primary completion for Dec 2022, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2021
First posted
Nov 12, 2021
StartEst.
Mar 1, 2022
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Apr 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05118763
Lead sponsor
ENA Respiratory Pty Ltd
Responsible party
Sponsor
First posted
Nov 12, 2021
Start date
Mar 1, 2022 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Apr 14, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INNA-051

Start the discussion